Anbio Biotechnology (NNNN)

Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Revenue	9.5	6.71	23.54
Revenue Growth (YoY)	-	-71.49%	-
Cost of Revenue	-	3.35	10.98
Gross Profit	5.47	3.36	12.56
Selling, General & Admin	-	1.27	2.17
Research & Development	-	0.13	0.2
Operating Expenses	-	1.4	2.37
Operating Income	4.14	1.96	10.2
Interest Expense / Income	-0.29	-0.17	-0.03
Other Expense / Income	0.09	-0.13	0.22
Pretax Income	4.33	2.25	10.01
Net Income	4.33	2.25	10.01
Net Income Growth	-	-77.49%	-
Free Cash Flow	-0.63	0.9	4.45
Gross Margin	57.61%	50.07%	53.36%
Operating Margin	43.55%	29.22%	43.30%
Profit Margin	45.57%	33.58%	42.52%
Free Cash Flow Margin	-6.67%	13.38%	18.90%
EBITDA	4.05	2.1	9.98
EBITDA Margin	42.59%	31.29%	42.40%
Depreciation & Amortization	0	0.01	0.01
EBIT	4.04	2.09	9.98
EBIT Margin	42.55%	31.11%	42.37%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).